HomeCompareFREQ vs ORCC

FREQ vs ORCC: Dividend Comparison 2026

FREQ yields 667.56% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FREQ wins by $614802.03M in total portfolio value
10 years
FREQ
FREQ
● Live price
667.56%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$614802.06M
Annual income
$474,868,230,549.69
Full FREQ calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — FREQ vs ORCC

📍 FREQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFREQORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FREQ + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FREQ pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FREQ
Annual income on $10K today (after 15% tax)
$56,742.32/yr
After 10yr DRIP, annual income (after tax)
$403,637,995,967.24/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, FREQ beats the other by $403,637,995,966.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FREQ + ORCC for your $10,000?

FREQ: 50%ORCC: 50%
100% ORCC50/50100% FREQ
Portfolio after 10yr
$307401.04M
Annual income
$237,434,115,275.37/yr
Blended yield
77.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

FREQ
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$1.40
+367.3% upside vs current
Range: $1.40 — $1.40
Altman Z
-7.4
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FREQ buys
0
ORCC buys
0
No recent congressional trades found for FREQ or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFREQORCC
Forward yield667.56%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$614802.06M$21.4K
Annual income after 10y$474,868,230,549.69$1.04
Total dividends collected$603369.48M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$1.40$16.00

Year-by-year: FREQ vs ORCC ($10,000, DRIP)

YearFREQ PortfolioFREQ Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$77,456$66,755.67$11,190$489.61+$66.3KFREQ
2$566,112$483,234.18$12,229$256.01+$553.9KFREQ
3$3,906,567$3,300,827.31$13,216$130.74+$3.89MFREQ
4$25,467,892$21,287,865.51$14,207$66.02+$25.45MFREQ
5$156,952,466$129,701,821.96$15,234$33.17+$156.94MFREQ
6$914,968,107$747,028,968.25$16,317$16.62+$914.95MFREQ
7$5,048,988,394$4,069,972,519.36$17,468$8.32+$5048.97MFREQ
8$26,392,111,970$20,989,694,387.90$18,695$4.16+$26392.09MFREQ
9$130,779,275,796$102,539,715,988.68$20,006$2.08+$130779.26MFREQ
10$614,802,055,652$474,868,230,549.69$21,407$1.04+$614802.03MFREQ

FREQ vs ORCC: Complete Analysis 2026

FREQStock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Full FREQ Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this FREQ vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FREQ vs SCHDFREQ vs JEPIFREQ vs OFREQ vs KOFREQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.